BREAKING NEWS

BREAKING NEWS

Roche's Tecentriq wins speedy U.S. review in small cell lung cancer

Now Reading :

Roche's Tecentriq wins speedy U.S. review in small cell lung cancer

Roche's Tecentriq wins speedy U.S. review in small cell lung cancer
@ Copyright :
ARND WIEGMANN(Reuters)
Text size Aa Aa

ZURICH (Reuters) - Roche's <ROG.S> Tecentriq immunotherapy with chemotherapy won priority review in the United States for the initial treatment of extensive-stage small cell lung cancer (SCLC), the company said, setting up possible approval by March 18.

Wednesday's announcement comes after Roche in September said patients with untreated extensive-stage SCLC, where cancer has spread, lived a median 12.3 months after getting Tecentriq plus chemotherapy, compared to 10.3 months for those on just chemotherapy.

(Reporting by John Miller; editing by Thomas Seythal)

euronews provides breaking news articles from reuters as a service to its readers, but does not edit the articles it publishes. Articles appear on euronews.com for a limited time.